Introduction
Luc's University Hospital, Avenue Hippocrate 10, 1200 Brussels, Ovarian stimulation is now routinely used in IVF and other pro- Belgium, 4 Academic Hospital St Radboud, Department of grammes using assisted reproduction techniques (Hamberger Obstetrics and Gynaecology, G. Grooteplein Zuid 16, 6525 GA Nijmegen, The Netherlands, and 5 Centre for Reproductive and Wikland, 1993) . The likelihood of pregnancy and a Medicine, University Hospital of the Dutch speaking Brussels Free subsequent live birth appears to be determined by the presence University, Laarbeeklaan 101, B-1090 Brussels, Belgium of multiple fertilized oocytes rather than by the number of embryos transferred (Templeton and Morris, 1998) . This 6 Present address: Maternité Grande Duchesse Charlotte, Rue Barblé 4, L-1210 Luxembourg knowledge is welcome, as multiple births following the replacement of large numbers of embryos lead to excessive morbidity 7 To whom correspondence should be addressed at: Academic Hospital 'Vrije Universiteit' Amsterdam, Department of Obstetrics among survivors, with considerable medical, social and finanand Gynaecology, Subdivision: Reproductive Endocrinology and cial consequences (Templeton and Morris, 1998) . There remains, nevertheless, some degree of controversy Netherlands. E-mail: r.schats@azvu.nl over the most appropriate method of ovarian stimulation. One commonly used protocol-selected as the basis for the present This randomized, single-blind, multicentre, multinational study compared recombinant human FSH (rhFSH, Gonalstudy-involves long desensitization with a gonadotrophinreleasing hormone (GnRH) agonist and the daily use of FSH F ® ) with highly purified urinary human FSH (uhFSH, Metrodin HP ® ) in women undergoing ovarian stimulation to bring about multiple follicular development. Desensitization suppresses production of endogenous gonadotrophins and the for IVF/intracytoplasmic sperm injection (ICSI). Following desensitization in a long gonadotrophin-releasing hormone spontaneous, mid-cycle LH surge. As a result, there are fewer cancelled cycles, higher numbers of oocytes and more (GnRH) agonist protocol, patients received s.c. Gonal-F ® or Metrodin HP ® , at a fixed dose of 150 IU, until there pregnancies (Smitz et al., 1987; Loumaye, 1990; Hughes et al., 1992) . Until recently, FSH could only be obtained from human was adequate follicular development. Of 496 women randomized, 232 and 231 in the Gonal-F ® and Metrodin HP ® menopausal gonadotrophin (HMG) or other urine-derived preparations. These are impure and require the collection of vast groups respectively received human chorionic gonadotrophin (HCG). The duration of FSH treatment was signiquantities of urine, leading to an unreliable supply and, perhaps most importantly, batch-to-batch inconsistency. Gonal-F, the ficantly shorter with Gonal-F ® than with Metrodin HP ® (11.6 ⍨ 1.9 days versus 12.4 ⍨ 2.7 days; P < 0.0001) and first recombinant human FSH (rhFSH) preparation avoids these problems due to advances in recombinant biotechnology. significantly fewer ampoules were required (mean 22.6 ⍨ 5.0 versus 24.3 ⍨ 5.1, P < 0.0002). There were, however, Gonal-F, with a specific activity of more than 10 000 IU/mg protein (Loumaye et al., 1995) is devoid of any LH activity, significantly more follicles ≥10 mm in diameter with Gonal-F ® (15.6 ⍨ 8.2 versus 13.6 ⍨ 7.1, P < 0.01) and oocytes and it is this high purity which is thought to confer safety and tolerability advantages over urine-derived human FSH (uhFSH) retrieved (13.1 ⍨ 7.7 versus 11.4 ⍨ 7.6, P < 0.002). Although no statistical difference in pregnancy rate was (Redfearn et al., 1995; Albano et al., 1996) . In clinical terms rhFSH, in comparison with highly purified recorded, patients receiving Gonal-F ® had a higher pregnancy rate per cycle than patients given Metrodin HP ® uhFSH, is associated with improved stimulation of multifollicular development, without any increase in the risk of the (25.1 versus 20.1%). Moderate to severe ovarian hyperstimulation syndrome occurred in 2.8 and 1.2% of Gonalovarian hyperstimulation syndrome (OHSS) (Out et al., 1995; Bergh et al., 1997; Frydman et al., 1998; Khalaf et al., 1998) . F ® and Metrodin HP ® patients respectively (not significant).
In conclusion, FSH stimulation in combination with a long
It is not yet fully understood why rhFSH should be more effective than urinary preparations of FSH, though differences GnRH agonist protocol is effective in inducing multiple follicular development and embryos with a high implantain pharmaceutical formulation and the presence of slightly extraction or percutaneous epididymal sperm aspiration procedures.
more basic isoforms of FSH in rhFSH (de Leeuw et al., 1996;  The most common causes of infertility were male factor (~50%) and D'Antonio et al., 1999) There remains a question mark over the optimal starting were to be avoided. Patients requiring these agents were only permitted dose of rhFSH, and another over the possibility of reducing to continue in the trial at the investigator's discretion.
overall rhFSH consumption. These issues are important not only from a clinical perspective, but also from an economic
Study design
one. An earlier study (Camier et al., 1998) HP ® ). Thus, overall, the data suggest that rhFSH is likely to
The study was conducted in accordance with the requirements of the be advantageous from a clinical and cost-benefit perspective.
Declaration of Helsinki and Good Clinical Practice (GCP) guidelines.
The latter is currently being investigated using a sophisticated form as part of a meta-analysis in which data from 12 different thickness of Ͻ7 mm, and if serum oestradiol concentrations were trials were pooled (Daya and Gunby, 1999) .
ഛ50 pg/ml (185 pmol/l). After desensitization, patients received either Gonal-F ® or Metrodin HP ® administered once daily, s.c., starting at a fixed dose of 150 IU/
Materials and methods
day for the first 6 days. Ovarian response was assessed on day 7, Patient selection and the results were used to evaluate whether the dose needed to be reduced. Ovarian response was regarded as high if in total ജ20 Patients were recruited between November 1996 and August 1998. Randomization was carried out with computer-generated numbers.
follicles and/or oestradiol concentrations already Ͼ5000 pmol/l were detected. If the response was satisfactory, patients continued on a Women with regular, spontaneous menstrual cycles of 25-35 days, aged 18-38 years, were eligible if they fulfilled the following criteria: fixed dose of 150 IU FSH/day until HCG was administered. Patients with a poor response were withdrawn and, in cases of an excessive (i) infertility attributable to any of the following-a tubal factor, grade I or II endometriosis (American Fertility Society, 1985) , poor response, patients judged to be at risk of OHSS had oocyte retrieval and any resultant embryos frozen for replacement in a subsequent cycle. spermatozoa indicative of IVF or ICSI treatment, or unexplained infertility; (ii) serum concentrations of FSH and LH within the GnRH agonist (GnRHa) and FSH were administered until the largest follicle had a mean diameter of ജ18 mm, there were at least local laboratory normal range, prolactin concentrations Ͻ20 ng/ml, testosterone concentrations Ͻ3.5 nmol/l; (iii) no more than two two other follicles with a diameter of ജ16 mm and if the patient's oestradiol concentration was within an acceptable range (500 pmol previous assisted reproduction treatment cycles; (iv) body mass index ജ18 but ഛ28 kg/m 2 ; (v) presence of both ovaries and normal uterine oestradiol/follicle). HCG (Profasi ® , Serono Benelux b.v.) was administered s.c. at a dose of 10 000 IU, within 24 h of the last dose of cavity; (vi) no treatment with clomiphene citrate or gonadotrophins in the month prior to the study; and (vii) willingness to participate GnRHa and FSH. Oocytes were retrieved 34-38 h after HCG administration and in the study and to comply with procedures. All patients gave their written informed consent.
their nuclear maturity assessed according to established criteria as germinal vesicle, metaphase I, metaphase II, atretic or unknown. Patients were excluded from the study if they had: (i) abnormal gynaecological bleeding of undetermined origin; (ii) a previous IVF They were then fertilized in vitro, and the resultant embryos graded. Up to three embryos were replaced, 2-4 days after oocyte retrieval. or ICSI failure due to a poor response to gonadotrophins or a previous ICSI failure due to a problem of sperm fertilization (Ͻ20%); (iii) a For ICSI, the cumulus cells were removed and an assessment of oocyte nuclear maturity was made. Any remaining embryos were previous history of severe OHSS; (iv) a male partner with azoospermia and clinical signs of infection detected in a semen analysis within frozen at the 2-or 4-cell stage. Luteal phase support was initiated after oocyte retrieval using a commercially available progesterone the past 12 months; (v) a clinically significant condition/disease; or (vi) microsurgical epididymal sperm aspiration, testicular sperm preparation (Progestan ® /Utrogestan ® ; Nourypharma, Oss, The Netherlands) at a dose of 200 mg three times daily, intravaginally. The two treatment groups were comparable for demographic one which was judged by the investigator to be probably or possibly characteristics (Table I ). Of the 496 randomized patients, 442
related to the study drug.
(89%) had oocyte retrieval and 402 (81%) completed the study up to embryo transfer (Table II because of mild OHSS (n ϭ 1); another two patients withdrew either because of illness or for personal reasons.
Statistics

Statistical analyses (SAS program) were performed on all data
Stimulation characteristics available. The set of patients used for the analyses was based on the Table III shows the stimulation characteristics for all patients ITT (intention-to-treat) principle and included all randomized patients who received HCG. The comparability of the two treatment groups who received HCG. Both the number of FSH treatment days was checked for all demographic data, and both this and the efficacy and total number of 75 IU ampoules used were statistically data were evaluated using summary statistics (n, mean, SD, minimum significantly lower (P Ͻ 0.0001 and P Ͻ 0.0002 respectively) and maximum for continuous variables and frequencies and percentfor Gonal-F ® than for Metrodin HP ® . Therefore, overall FSH ages for categorical data). Differences between groups were analysed consumption in 75 IU ampoule equivalents was significantly using Wilcoxon two-sample or χ 2 tests. Parametric tests, which are less (P Ͻ 0.001) in the Gonal-F ® group. Although the total known to have a higher power to detect a statistically significant number of ampoules of FSH used was lower in patients effect, e.g. analysis of variance on raw data, compared with nonreceiving Gonal-F ® , both the number of follicles ജ10 mm in parametric test such as a Wilcoxon two-sample t-test were not used diameter on the day of HCG and the number of oocytes because there was some doubt about ascertaining and confirming the retrieved were greater than in the Metrodin HP ® group. The normality and homogeneity of variance, assumptions required to use ratio of oocytes retrieved/FSH ampoule consumed was 0.58 a parametric test. This was mainly caused by the multicentre design of the study for the Gonal-F ® group and 0.47 for the Metrodin HP ® group. ( Table V) , with means of 2.1 Ϯ 0.6 and 2.1 Ϯ 0.5 embryos replaced in the two groups respectively. The overall clinical pregnancy rates per oocyte retrieval, per cycle and per embryo The results followed a similar pattern in the three subgroups transfer were all higher in the patients receiving Gonal-F ® , (IVF, ICSI and IVF ϩ ICSI; Table III ). For each of the though the differences between groups did not reach statistical subgroups, the duration of FSH treatment, numbers of ampoules significance (Table V) . The overall number of deliveries (live used and overall FSH consumption were lower for Gonal-F ® births) was not significantly different when comparing the than for Metrodin HP ® . As for the total study population, there Gonal-F ® group (28% per embryo transferred) with the Metrowere also higher number of follicles ജ10 mm in diameter and din HP ® group (21.5% per embryo transferred). However, the oocytes retrieved in the Gonal-F ® treatment group. There were difference in clinical pregnancy rate between treatment groups no marked differences between subgroups in most of the reached statistical significance on χ 2 analysis for the IVF (40 variables, though more oocytes were retrieved from the ICSI versus 27.6%, P ϭ 0.037) and IVF ϩ ICSI (80 versus 33.3%, subgroup, irrespective of treatment. P ϭ 0.040) subgroup patients.
Embryological characteristics Safety A total of 442 patients had oocyte retrieval; the embryological Of the 496 patients enrolled in the study, nine (2%) experienced characteristics are shown in Table IV . Significantly more moderate to severe OHSS; seven in the Gonal-F ® group (2.8%) oocytes were inseminated in the Gonal-F ® group than in the and two in the Metrodin HP ® group (1.2%). This difference Metrodin HP ® group (P Ͻ 0.003). The number of 2PN cleaved was not statistically significant. Other serious adverse events embryos was similar between groups, as were the numbers of related to the study drugs were not observed. cryopreserved embryos.
Again, these results followed a similar pattern in the three Discussion subgroups (IVF, ICSI and IVF ϩ ICSI), with higher numbers of inseminated oocytes and 2PN fertilized oocytes in the This multicentre study is the largest, to date, to compare the efficacy and safety of a recombinant human FSH preparation Gonal-F ® subgroups. Other variables were similar between treatment groups. Although there were no marked differences (Gonal-F ® ) with a purified urinary human FSH preparation (Metrodin HP ® ) in a group of women undergoing ovarian between subgroups, for patients undergoing ICSI, the mean number of 2PN fertilized oocytes was higher than for patients stimulation for IVF or ICSI. As pretreatment, the women were initially desensitized using a long luteal GnRH agonist protocol. undergoing IVF, irrespective of treatment group. To date, one similar study has been published in full (Bergh recruitment (P ഛ 0.004) and oocyte retrieval (P ഛ 0.001) with Gonal-F ® . In a third study (Khalaf et al., 1998 (Khalaf et al., ), although a et al., 1997 . In both study designs, the protocol used a low starting dose of FSH (150 IU/day), which has been shown lower FSH consumption was associated with a statistically higher number of aspirated follicles (P Ͻ 0.04), the difference previously to be as effective as a 225 IU dose for multiple follicular development (Camier et al., 1998) . Unlike in the in consumption between groups was not statistically different. This was because patients were started on up to 225 IU FSH previous study (Bergh et al., 1997) , the dose of FSH was kept constant throughout treatment (unless there was a risk per day, and not on a fixed dose. Although each centre has its own policy regarding timing and method for changing of OHSS).
The primary endpoints in this study were the total number gonadotrophin dose-meaning that one must be a little cautious in comparing FSH consumption across studies-in the studies of 75 IU ampoules of FSH used and the number of follicles ജ10 mm in diameter on the day of HCG administration. Both by Bergh et al. (1997) and Frydman et al. (1998) respectively, the number of FSH treatment days was 11.0 Ϯ 1.6 and 11.7 treatments induced good follicular recruitment (15.6 Ϯ 8.2 for Gonal-F ® versus 13.6 Ϯ 7.1 for Metrodin HP ® ), confirming Ϯ 1.9 for Gonal-F ® compared with 13.5 Ϯ 3.7 and 14.5 Ϯ 3.3 for Metrodin HP ® (P ഛ 0.001). The numbers of FSH the effectiveness of the 150 IU starting dose. The difference between the two groups, however, was statistically significant ampoules used in these studies were 21.9 Ϯ 5.1 and 27.6 Ϯ 10.2 for Gonal-F ® compared with 31.9 Ϯ 13.4 and 40.7 Ϯ (P Ͻ 0.01) in favour of Gonal-F ® . Additionally, the significantly higher level of follicular recruitment with Gonal-F ® was 13.6 for Metrodin HP ® (P ഛ 0.001). The greater number of ampoules used in one of these studies (Frydman et al., 1998 ) produced using statistically fewer 75 IU ampoules of FSH (22.6 Ϯ 5.0 versus 24.3 Ϯ 5.1, P Ͻ 0.0002) over a statistically compared with the numbers used in the present study and that by Bergh et al. (1997) may be partly explained by Frydman shorter treatment time than with Metrodin HP ® (11.6 Ϯ 1.9 days versus 12.4 Ϯ 2.7 days, P Ͻ 0.0001). In terms of the et al.'s use of a depot agonist in about 90% of patients treated, which would have caused a more profound level of numbers of oocytes retrieved, following HCG, Gonal-F ® was, again, statistically more effective than Metrodin HP ® . A mean desensitization than that following intranasal or s.c. administration of a GnRH agonist. of 13.1 Ϯ 7.7 oocytes were retrieved from patients who had received Gonal-F ® , compared with only 11.4 Ϯ 7.6 oocytes All of these results are consistent with a previous report , which described a higher bioactivity from patients receiving Metrodin HP ® (P Ͻ 0.002). Thus, this study clearly demonstrates the higher clinical efficacy of for rhFSH compared with urine-derived products, despite similar or lower serum immunoactive FSH concentrations. Gonal-F ® in inducing multiple follicular development.
Two previous studies (Bergh et al., 1997; Frydman et al., rhFSH is known to contain slightly more basic isoforms than urine-derived hFSH (de Leeuw et al., 1996) , and these have 1998), which compared Gonal-F ® with Metrodin HP ® , using an initial starting dose of 150 IU FSH, have demonstrated a higher intrinsic bioactivity and receptor affinity than acidic isoforms in vitro. Whether this is important for in-vivo human similar results, providing more support for the higher efficacy of the recombinant product. They (Bergh et al., 1997; Frydman bioactivity is not clear (Von Düring et al., 1999) . A limitation of the present study was that data on oestradiol et al., 1998) reported statistically lower FSH consumption (P ഛ 0.001), combined with statistically higher follicular
were not available for analysis because all oestradiol determina-tions were carried out locally in the participating centres, using In conclusion, Gonal-F ® and Metrodin HP ® , at a fixed starting dose of 150 IU/day for 6 days, were both highly different assays. Higher oestradiol concentrations on the day of HCG administration have been reported in rFSH-stimulated effective in producing multiple follicular development, and were well tolerated in this group of women undergoing IVF cycles when compared with those performed with highly purified uFSH in normal (Bergh et al., 1997) and poor (Raga or ICSI. Gonal-F ® was shown to be more efficacious, producing a significantly higher level of follicular recruitment and a et De Placido et al., 2000) responders.
Significantly more oocytes were inseminated in the Gonalgreater number of oocytes than Metrodin HP ® , combined with a statistically lower consumption of FSH. F ® group than in the Metrodin HP ® group (12.1 Ϯ 6.9 versus 10.1 Ϯ 6.0, P Ͻ 0.003). The mean number of 2PN fertilized oocytes was also higher for Gonal-F ® (7.2 Ϯ 5.4) than for Metrodin HP ® (6.4 Ϯ 4.9), though this difference was not
